ANGO vs. ARAY, SRDX, CTSO, OFIX, UTMD, TLSI, INO, RCEL, SGHT, and LUNG
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Accuray (ARAY), Surmodics (SRDX), Cytosorbents (CTSO), Orthofix Medical (OFIX), Utah Medical Products (UTMD), TriSalus Life Sciences (TLSI), Inovio Pharmaceuticals (INO), AVITA Medical (RCEL), Sight Sciences (SGHT), and Pulmonx (LUNG). These companies are all part of the "surgical & medical instruments" industry.
AngioDynamics (NASDAQ:ANGO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Accuray has a net margin of -3.25% compared to AngioDynamics' net margin of -60.21%. AngioDynamics' return on equity of -3.48% beat Accuray's return on equity.
AngioDynamics currently has a consensus price target of $14.25, suggesting a potential upside of 145.27%. Accuray has a consensus price target of $8.25, suggesting a potential upside of 276.71%. Given Accuray's higher possible upside, analysts plainly believe Accuray is more favorable than AngioDynamics.
In the previous week, Accuray had 3 more articles in the media than AngioDynamics. MarketBeat recorded 3 mentions for Accuray and 0 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.00 equaled Accuray'saverage media sentiment score.
AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
AngioDynamics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 5.1% of AngioDynamics shares are owned by company insiders. Comparatively, 3.8% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
AngioDynamics and Accuray tied by winning 8 of the 16 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
